Fairmount Funds Management LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Fairmount Funds Management LLC | 3,202,798 6.800% | 1,071,429![]() (+50.27%) | Filing |
2024-02-14 3:45 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | Fairmount Funds Management LLC | 2,131,369 5.200% | 6,744![]() (+0.32%) | Filing |
2023-04-27 10:00 am Purchase | 2023-04-18 | 13G | Enliven Therapeutics, Inc. ELVN | Fairmount Funds Management LLC | 2,124,625 5.170% | 2,124,625![]() (New Position) | Filing |